HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors

Elizabeth Half, Russell Broaddus, Kathleen D. Danenberg, Peter V. Danenberg, Gregory D. Ayers, Frank A Sinicrope

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The HER-2/neu oncogene encodes a 185 kD protein that is phosphorylated upon ligand binding to other HER/erbB members and regulates cell growth and differentiation. Given that HER-2 receptor blockade can inhibit the growth of colon cancer cell lines and tumor xenografts, we investigated the frequency, localization and phosphorylation status of HER-2 in colon cancer cell lines and in human tumors. Protein expression was analyzed in relation to mRNA levels, HER-2 amplification, and clinicopathological variables. Colon cancer cell lines constitutively expressed HER-2 proteins and none showed HER-2 amplification by fluorescence in situ hybridization. Cell fractionation and immunoblotting showed HER-2 in both the membrane and cytosolic compartments. Primary colorectal carcinomas (n = 96) and their metastases (n = 25) were examined by immunohistochemistry. Strong membrane HER-2 staining was detected in 5 (5%) of primaries and in 3 (12%) metastases (p = 0.36). Membrane but not cytoplasmic localization was strongly associated with HER-2 gene amplification (p = 0.007). Cytoplasmic HER-2 staining was found in 61 (63.5%) of primary tumors and localization was confirmed by immunoelectron microscopy that also showed plasma membrane HER-2. Using real-time quantitative RT-PCR, HER-2 mRNA was increased in tumors with membrane compared to cytoplasmic staining (r = 0.66, p = 0.001). Cytoplasmic HER-2 was associated with tumor differentiation (p = 0.018), but not other clinicopathological variables. By immunoblotting, heterogeneity was seen in HER-2 levels with downregulation in 4 of 7 tumors relative to normal epithelia that uniformly expressed HER-2. Phosphorylated HER-2 was detected in approximately 50% of tumors and in normal mucosa. In conclusion, HER-2 is expressed constitutively in colon cancer cell lines and demonstrates relatively distinct localization patterns in human tumors. Strong membrane immunoreactivity is associated with high levels of HER-2 mRNA and gene amplification whereas cytoplasmic HER-2 is detected frequently and seems to be a marker of tumor differentiation.

Original languageEnglish (US)
Pages (from-to)540-548
Number of pages9
JournalInternational Journal of Cancer
Volume108
Issue number4
DOIs
StatePublished - Feb 4 2004

Fingerprint

Tumor Cell Line
Colorectal Neoplasms
Colonic Neoplasms
Neoplasms
erbB-2 Genes
Membranes
Gene Amplification
Staining and Labeling
Immunoblotting
Cell Line
Messenger RNA
Cell Membrane
Neoplasm Metastasis
Cell Fractionation
Proteins
Immunoelectron Microscopy
Differentiation Antigens
Tumor Biomarkers
Growth
Fluorescence In Situ Hybridization

Keywords

  • Colorectal cancer
  • HER2/neu (c-erbB-2)
  • Phosphorylation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. / Half, Elizabeth; Broaddus, Russell; Danenberg, Kathleen D.; Danenberg, Peter V.; Ayers, Gregory D.; Sinicrope, Frank A.

In: International Journal of Cancer, Vol. 108, No. 4, 04.02.2004, p. 540-548.

Research output: Contribution to journalArticle

Half, Elizabeth ; Broaddus, Russell ; Danenberg, Kathleen D. ; Danenberg, Peter V. ; Ayers, Gregory D. ; Sinicrope, Frank A. / HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. In: International Journal of Cancer. 2004 ; Vol. 108, No. 4. pp. 540-548.
@article{8b3c7b9e910f404caafe860caf2219bd,
title = "HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors",
abstract = "The HER-2/neu oncogene encodes a 185 kD protein that is phosphorylated upon ligand binding to other HER/erbB members and regulates cell growth and differentiation. Given that HER-2 receptor blockade can inhibit the growth of colon cancer cell lines and tumor xenografts, we investigated the frequency, localization and phosphorylation status of HER-2 in colon cancer cell lines and in human tumors. Protein expression was analyzed in relation to mRNA levels, HER-2 amplification, and clinicopathological variables. Colon cancer cell lines constitutively expressed HER-2 proteins and none showed HER-2 amplification by fluorescence in situ hybridization. Cell fractionation and immunoblotting showed HER-2 in both the membrane and cytosolic compartments. Primary colorectal carcinomas (n = 96) and their metastases (n = 25) were examined by immunohistochemistry. Strong membrane HER-2 staining was detected in 5 (5{\%}) of primaries and in 3 (12{\%}) metastases (p = 0.36). Membrane but not cytoplasmic localization was strongly associated with HER-2 gene amplification (p = 0.007). Cytoplasmic HER-2 staining was found in 61 (63.5{\%}) of primary tumors and localization was confirmed by immunoelectron microscopy that also showed plasma membrane HER-2. Using real-time quantitative RT-PCR, HER-2 mRNA was increased in tumors with membrane compared to cytoplasmic staining (r = 0.66, p = 0.001). Cytoplasmic HER-2 was associated with tumor differentiation (p = 0.018), but not other clinicopathological variables. By immunoblotting, heterogeneity was seen in HER-2 levels with downregulation in 4 of 7 tumors relative to normal epithelia that uniformly expressed HER-2. Phosphorylated HER-2 was detected in approximately 50{\%} of tumors and in normal mucosa. In conclusion, HER-2 is expressed constitutively in colon cancer cell lines and demonstrates relatively distinct localization patterns in human tumors. Strong membrane immunoreactivity is associated with high levels of HER-2 mRNA and gene amplification whereas cytoplasmic HER-2 is detected frequently and seems to be a marker of tumor differentiation.",
keywords = "Colorectal cancer, HER2/neu (c-erbB-2), Phosphorylation",
author = "Elizabeth Half and Russell Broaddus and Danenberg, {Kathleen D.} and Danenberg, {Peter V.} and Ayers, {Gregory D.} and Sinicrope, {Frank A}",
year = "2004",
month = "2",
day = "4",
doi = "10.1002/ijc.11599",
language = "English (US)",
volume = "108",
pages = "540--548",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors

AU - Half, Elizabeth

AU - Broaddus, Russell

AU - Danenberg, Kathleen D.

AU - Danenberg, Peter V.

AU - Ayers, Gregory D.

AU - Sinicrope, Frank A

PY - 2004/2/4

Y1 - 2004/2/4

N2 - The HER-2/neu oncogene encodes a 185 kD protein that is phosphorylated upon ligand binding to other HER/erbB members and regulates cell growth and differentiation. Given that HER-2 receptor blockade can inhibit the growth of colon cancer cell lines and tumor xenografts, we investigated the frequency, localization and phosphorylation status of HER-2 in colon cancer cell lines and in human tumors. Protein expression was analyzed in relation to mRNA levels, HER-2 amplification, and clinicopathological variables. Colon cancer cell lines constitutively expressed HER-2 proteins and none showed HER-2 amplification by fluorescence in situ hybridization. Cell fractionation and immunoblotting showed HER-2 in both the membrane and cytosolic compartments. Primary colorectal carcinomas (n = 96) and their metastases (n = 25) were examined by immunohistochemistry. Strong membrane HER-2 staining was detected in 5 (5%) of primaries and in 3 (12%) metastases (p = 0.36). Membrane but not cytoplasmic localization was strongly associated with HER-2 gene amplification (p = 0.007). Cytoplasmic HER-2 staining was found in 61 (63.5%) of primary tumors and localization was confirmed by immunoelectron microscopy that also showed plasma membrane HER-2. Using real-time quantitative RT-PCR, HER-2 mRNA was increased in tumors with membrane compared to cytoplasmic staining (r = 0.66, p = 0.001). Cytoplasmic HER-2 was associated with tumor differentiation (p = 0.018), but not other clinicopathological variables. By immunoblotting, heterogeneity was seen in HER-2 levels with downregulation in 4 of 7 tumors relative to normal epithelia that uniformly expressed HER-2. Phosphorylated HER-2 was detected in approximately 50% of tumors and in normal mucosa. In conclusion, HER-2 is expressed constitutively in colon cancer cell lines and demonstrates relatively distinct localization patterns in human tumors. Strong membrane immunoreactivity is associated with high levels of HER-2 mRNA and gene amplification whereas cytoplasmic HER-2 is detected frequently and seems to be a marker of tumor differentiation.

AB - The HER-2/neu oncogene encodes a 185 kD protein that is phosphorylated upon ligand binding to other HER/erbB members and regulates cell growth and differentiation. Given that HER-2 receptor blockade can inhibit the growth of colon cancer cell lines and tumor xenografts, we investigated the frequency, localization and phosphorylation status of HER-2 in colon cancer cell lines and in human tumors. Protein expression was analyzed in relation to mRNA levels, HER-2 amplification, and clinicopathological variables. Colon cancer cell lines constitutively expressed HER-2 proteins and none showed HER-2 amplification by fluorescence in situ hybridization. Cell fractionation and immunoblotting showed HER-2 in both the membrane and cytosolic compartments. Primary colorectal carcinomas (n = 96) and their metastases (n = 25) were examined by immunohistochemistry. Strong membrane HER-2 staining was detected in 5 (5%) of primaries and in 3 (12%) metastases (p = 0.36). Membrane but not cytoplasmic localization was strongly associated with HER-2 gene amplification (p = 0.007). Cytoplasmic HER-2 staining was found in 61 (63.5%) of primary tumors and localization was confirmed by immunoelectron microscopy that also showed plasma membrane HER-2. Using real-time quantitative RT-PCR, HER-2 mRNA was increased in tumors with membrane compared to cytoplasmic staining (r = 0.66, p = 0.001). Cytoplasmic HER-2 was associated with tumor differentiation (p = 0.018), but not other clinicopathological variables. By immunoblotting, heterogeneity was seen in HER-2 levels with downregulation in 4 of 7 tumors relative to normal epithelia that uniformly expressed HER-2. Phosphorylated HER-2 was detected in approximately 50% of tumors and in normal mucosa. In conclusion, HER-2 is expressed constitutively in colon cancer cell lines and demonstrates relatively distinct localization patterns in human tumors. Strong membrane immunoreactivity is associated with high levels of HER-2 mRNA and gene amplification whereas cytoplasmic HER-2 is detected frequently and seems to be a marker of tumor differentiation.

KW - Colorectal cancer

KW - HER2/neu (c-erbB-2)

KW - Phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=0347417902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347417902&partnerID=8YFLogxK

U2 - 10.1002/ijc.11599

DO - 10.1002/ijc.11599

M3 - Article

C2 - 14696118

AN - SCOPUS:0347417902

VL - 108

SP - 540

EP - 548

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -